Innovative Category II drugs have emerged as a global hotspot in the pharmaceutical industry in recent years, representing a key direction for technological innovation prioritized by the state and a golden track favored by capital. Guangzhou DiQi has consistently prioritized the development of Category II innovative drugs as the core focus of its corporate strategy, establishing it as a long-term developmental objective. From March 25 to 26, 2023, Dr. Liu Feng, Chairman and General Manager of Guangzhou DiQi, was invited to participate in the “Improved Innovative Drugs and High-End Formulation R&D” sub-forum at the 8th China Pharmaceutical Formulation Festival. He delivered a keynote presentation titled “PLGA and Its New Advances in Drug Delivery.”
Dr. Liu Feng primarily outlined the research and development journey and key applications of poly(lactic-co-glycolic acid) (PLGA) in sustained-release formulations. He discussed the primary factors influencing drug delivery using PLGA and shared forward-looking perspectives on the future application directions of PLGA. His presentation was met with repeated applause from the association members, guests, and peers in attendance.
From the perspective of technological and product development trends, PLGA serves as an indispensable carrier for drug delivery, ensuring enhanced therapeutic efficacy, reduced toxicity and side effects, improved patient compliance, and prolonged therapeutic effects. Today, PLGA has been successfully applied in over twenty small-molecule and peptide drugs for extended-release formulations, generating a market exceeding fifty billion. It is believed that in the near future, protein drugs and nucleic acid drugs based on PLGA extended-release technology will also shine brightly.
The development of Class II innovative drugs relies on the support of fundamental research, while innovation itself demands sustained investment and perseverance. DiQi embraces the mission of “creating high-quality, highly effective, long-acting, and highly compliant medicines,” focusing on independent innovation and the development and industrialization of modified innovative formulations and high-end excipients with proprietary intellectual property rights. Currently, DiQi's independently developed Category II innovative drug, Risperidone Microspheres for Injection (4W), has received clinical trial approvals from both the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). This milestone marks a significant stride forward for Guangzhou DiQi in its pursuit of becoming a “leading international enterprise in high-end pharmaceutical formulations.”
Return to List
